Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Phil J. Stephens"'
Autor:
Jon H. Chung, Siraj M. Ali, Jenni Davis, Karl Robstad, Richard McNally, Laurie M. Gay, Rachel L. Erlich, Norma A. Palma, Phil J. Stephens, Vincent A. Miller, Alfonso Cutugno, Jeffrey S. Ross
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 3, Pp 628-632 (2014)
Suspected metastatic site lesions that are poorly differentiated present a diagnostic challenge when morphologic and immunohistochemical profiling cannot establish the primary tumor site. Here we present a patient diagnosed with both a malignant neop
Externí odkaz:
https://doaj.org/article/da0701258f32419591a4068c8d7137be
Autor:
Norma A. Palma, Siraj M. Ali, Jamie O'Connor, Deepa Dutta, Kai Wang, Salil Soman, Gary A. Palmer, Deborah Morosini, Jeffrey S. Ross, Doron Lipson, Phil J. Stephens, Mayur Patel, Vincent A. Miller, Nicholas Koutrelakos
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 503-508 (2014)
Background: Carcinoma of unknown primary (CUP) accounts for 3-5% of all adult solid tumors. An extensive search for the anatomic site of origin is often undertaken in an attempt to tailor systemic treatment, but the latter often has limited efficacy
Externí odkaz:
https://doaj.org/article/c3e9468f60934015a6cc8287ab076e87
Autor:
Siraj M. Ali, Je He, Wade Carson, Phil J. Stephens, Joseph Fiorillo, Doron Lipson, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Jeffrey Sharman
Publikováno v:
Case Reports in Oncology, Vol 7, Iss 2, Pp 343-348 (2014)
Context: For patients with metastatic papillary thyroid carcinoma (PTC) refractory to radioactive iodine (RAI) treatment, systemic chemotherapy has limited efficacy. Such tumors frequently harbor BRAF V600E, and this alteration may predict responsive
Externí odkaz:
https://doaj.org/article/068b19060d6f45fe85af7a3c1eb32353
Autor:
Pasi A. Jänne, William G. Richards, Kiara J. Munir, Neal I. Lindeman, Vincent A. Miller, Phil J. Stephens, Lauren Young, Doron Lipson, David M. Jablons, Hidefumi Sasaki, Jhingook Kim, Seung-Il Park, Peter S. Hammerman, Dalia Ercan, Michael E. Dodge, Marzia Capelletti
Table S2. Genomic alterations across 576 lung adenocarcinomas grouped by ethnicity with description of the EGFR mutations. . "*" The "Unknown" population is the same of the pan-WT reported in the text.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::079eb229d54005ac50690b710a2ff164
https://doi.org/10.1158/1078-0432.22457792
https://doi.org/10.1158/1078-0432.22457792
Autor:
Pasi A. Jänne, William G. Richards, Kiara J. Munir, Neal I. Lindeman, Vincent A. Miller, Phil J. Stephens, Lauren Young, Doron Lipson, David M. Jablons, Hidefumi Sasaki, Jhingook Kim, Seung-Il Park, Peter S. Hammerman, Dalia Ercan, Michael E. Dodge, Marzia Capelletti
Purpose: Targetable oncogenic alterations are detected more commonly in patients with non–small cell lung cancer (NSCLC) who never smoked cigarettes. For such patients, specific kinase inhibitors have emerged as effective clinical treatments. Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc023eacaad5fa76d2a79d0b2d52511
https://doi.org/10.1158/1078-0432.c.6523694
https://doi.org/10.1158/1078-0432.c.6523694
Autor:
Pasi A. Jänne, William G. Richards, Kiara J. Munir, Neal I. Lindeman, Vincent A. Miller, Phil J. Stephens, Lauren Young, Doron Lipson, David M. Jablons, Hidefumi Sasaki, Jhingook Kim, Seung-Il Park, Peter S. Hammerman, Dalia Ercan, Michael E. Dodge, Marzia Capelletti
Figure S2. Haematoxylin and eosin staining of two patient samples with adenocarcinoma histology: A. CG-42. B. J2-109.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6398ece0d6cfa5c97763578e47e1e85b
https://doi.org/10.1158/1078-0432.22457801
https://doi.org/10.1158/1078-0432.22457801
Autor:
Justin M. Balko, Carlos L. Arteaga, Phillip K. Darcy, Sergey V. Ryzhov, Henry Gómez, Franco D. Doimi, Roman Yelensky, Phil J. Stephens, Vincent A. Miller, Kai Wang, Simon A. Mallal, Mark A. Pilkinton, Rebecca S. Cook, Melinda E. Sanders, Violeta Sánchez, Monica V. Estrada, Jennifer M. Giltnane, David L. Rimm, Susan Combs, Peter Savas, Carsten Denkert, Roberto Salgado, Paul A. Beavis, Sathana Dushyanthen, Sherene Loi
Supplemental Figure 1: No clear interaction of molecular subtype with change in TIL score dureing NAC. Supplemental Figure 2: No clear relationship between pre-NAC TILs or change in TILs with RFS or OS. Supplemental Figure 3: No clear association bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0574a7660ba58593369c7ac433d65e
https://doi.org/10.1158/1078-0432.22459212
https://doi.org/10.1158/1078-0432.22459212
Autor:
Justin M. Balko, Carlos L. Arteaga, Phillip K. Darcy, Sergey V. Ryzhov, Henry Gómez, Franco D. Doimi, Roman Yelensky, Phil J. Stephens, Vincent A. Miller, Kai Wang, Simon A. Mallal, Mark A. Pilkinton, Rebecca S. Cook, Melinda E. Sanders, Violeta Sánchez, Monica V. Estrada, Jennifer M. Giltnane, David L. Rimm, Susan Combs, Peter Savas, Carsten Denkert, Roberto Salgado, Paul A. Beavis, Sathana Dushyanthen, Sherene Loi
Purpose: Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with improved survival, but insight into tumor cell-autonomous molecular pathways
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7a4bdc594cd07d01d12a8f6184823c
https://doi.org/10.1158/1078-0432.c.6524160
https://doi.org/10.1158/1078-0432.c.6524160
Autor:
Justin M. Balko, Carlos L. Arteaga, Phillip K. Darcy, Sergey V. Ryzhov, Henry Gómez, Franco D. Doimi, Roman Yelensky, Phil J. Stephens, Vincent A. Miller, Kai Wang, Simon A. Mallal, Mark A. Pilkinton, Rebecca S. Cook, Melinda E. Sanders, Violeta Sánchez, Monica V. Estrada, Jennifer M. Giltnane, David L. Rimm, Susan Combs, Peter Savas, Carsten Denkert, Roberto Salgado, Paul A. Beavis, Sathana Dushyanthen, Sherene Loi
Supplementary figure legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d1459067fb09f90565c419447cda938
https://doi.org/10.1158/1078-0432.22459209
https://doi.org/10.1158/1078-0432.22459209
Autor:
Allison, Greenplate, Kai, Wang, Rati M, Tripathi, Norma, Palma, Siraj M, Ali, Phil J, Stephens, Vincent A, Miller, Yu, Shyr, Yan, Guo, Nishitha M, Reddy, Lina, Kozhaya, Derya, Unutmaz, Xueyan, Chen, Jonathan M, Irish, Utpal P, Davé
Publikováno v:
JCO precision oncology
Purpose The promise of precision oncology is that identification of genomic alterations will direct the rational use of molecularly targeted therapy. This approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::73b63c7139d25b4ed5eeca9108f2e18f
https://pubmed.ncbi.nlm.nih.gov/30079384
https://pubmed.ncbi.nlm.nih.gov/30079384